Relationship between plasma antifactor Xa activity and the antithrombotic activity of heparins of different molecular mass

Haemostasis
P BianchiniB Osima

Abstract

The relationship between the inhibition of venous thrombosis and antifactor Xa (AXa) plasma levels, measured as ex vivo AXa activity at the moment of experimental thrombosis induction, was evaluated in rats treated by different administration routes with different doses of heparins of various molecular masses: unfractionated heparin (UH, 13 kDa), low-molecular-mass heparin (LMM-H, 5kD) and oligo-heparin (OL-H, 2 kD). The AXa activity levels of plasma samples were measured by an amidolytic method and expressed in AXa U/ml. The antithrombotic effect was determined by a vena cava ligature model and expressed as the percent inhibition of thrombus weight. A correlation between the two parameters was determined, regardless of the administration route used. Every heparin requires different AXa plasma levels to develop the same antithrombotic activity: the plasma concentration inducing a 50% protection was 0.09, 0.12 and 0.15 AXa U/ml, for UH, LMM-H and OL-H, respectively. Oligo-H has a significant antithrombotic activity when delivered by the intraileal route and the time course pharmacodynamics showed two phases for the parameters considered: in the second phase, a dissociation between AXa plasma level and antithrombotic effect was o...Continue Reading

Citations

Apr 18, 2007·Annals of Hematology·Maria Jesús BruscasUNKNOWN RIETE Investigators
Mar 21, 2007·Pharmaceutical Research·Vjera GrabovacAndreas Bernkop-Schnürch
May 8, 2004·International Journal of Pharmaceutics·Y V Rama PrasadKanji Takada
Dec 14, 2011·International Journal of Nanomedicine·Alyaa RamadanJean Pierre Benoit
Jan 12, 2002·Biochemical and Biophysical Research Communications·Stefania PaciniMarco Ruggiero
Nov 30, 2013·Journal of Aerosol Medicine and Pulmonary Drug Delivery·Brijeshkumar PatelFakhrul Ahsan
Jan 29, 2013·Journal of Drug Targeting·Canan IskenderoğluYeşim Bardakçi
Nov 26, 2009·Drug Development and Industrial Pharmacy·Julien Scala-BertolaPhilippe Maincent
Feb 9, 2007·Journal of Pharmaceutical Sciences·Shuhua BaiFakhrul Ahsan
Feb 6, 2004·Journal of Pharmaceutical Sciences·Fatima MustafaFakhrul Ahsan
Jun 9, 2009·International Journal of Pharmaceutics·Barbara RuoziMaria Angela Vandelli
May 13, 2008·Journal of Controlled Release : Official Journal of the Controlled Release Society·Amit RawatFakhrul Ahsan
Apr 28, 2006·The Journal of Pharmacy and Pharmacology·Nusrat Abbas MotlekarBi-Botti Celestin Youan
Jul 18, 2012·Journal of Controlled Release : Official Journal of the Controlled Release Society·Brijeshkumar PatelFakhrul Ahsan
Feb 26, 2004·The Journal of Pharmacy and Pharmacology·Tianzhi YangFakhrul Ahsan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.